SINOPHARM TECH issued a profit warning, expecting the annual loss attributable to shareholders to not exceed HKD 1 million, a significant decrease of approximately 95% year-on-year
SINOPHARM TECH expects that the annual loss attributable to the company's owners for the year ending June 30, 2025, will not exceed HKD 1 million, a significant decrease of approximately 95% year-on-year. The main factors contributing to the improvement in financial performance include a business improvement leading to an increase in gross profit of approximately HKD 9.2 million, strengthened cost control, capitalized loan income of approximately HKD 3.9 million, and reduced financing costs
According to the Zhitong Finance APP, SINOPHARM TECH (08156) announced that it expects the group to achieve a loss attributable to the company's owners of no more than HKD 1 million for the year ending June 30, 2025, a significant decrease of approximately 95% year-on-year. The board believes that the substantial improvement in the group's financial performance during the reporting period is mainly due to the net impact of the following factors: (i) business improvement leading to a year-on-year increase in gross profit of approximately HKD 9.2 million or 184%; (ii) strengthened cost control over administrative and operational expenses; (iii) loan capitalization gains of approximately HKD 3.9 million during the reporting period; and (iv) a reduction in financing costs during the reporting period due to loan capitalization
